-
Since 2022, more than 6 multinational pharmaceutical company executives have left
Time of Update: 2022-04-28
On February 24, Abbott's internal news said that the organizational structure of the core diagnostics business unit was adjusted, and Tony Chan, Abbott's global vice president and president of China's core diagnostics, decided to seek external opportunities .
-
Gan & Lee Pharmaceuticals opens first human trial of experimental drug GZR18
Time of Update: 2022-04-28
GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential for the treatment of patients with type 2 diabetes .
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
-
The results of the selection of 276 drugs for centralized procurement have been released, and some drugs have dropped by more than 98%!
Time of Update: 2022-04-28
The results of this alliance centralized procurement show that three companies, Changchun High-tech, Anke Bio, and Novo Nordisk, abandoned the bid or did not offer an offer for growth hormone water injection.
-
Tide Pharmaceutical's "Colesevelam Hydrochloride Tablets" was approved by the US ANDA
Time of Update: 2022-04-28
Colesevelam hydrochloride tablet is a non-absorbable polymer oral drug, used alone or in combination with any statin, which can be used as an adjunctive treatment for primary hyperlipidemia diet and exercise to reduce patient Elevated low-density lipoprotein cholesterol (LDL-C) levels; also used to aid diet and exercise control to improve glycemic control in adults with type 2 diabetes .
-
Last week, 7 pharmaceutical and biological companies disclosed their performance reports!
Time of Update: 2022-04-28
Last week (March 7-13), another batch of pharmaceutical and biological companies disclosed their 2021 performance reports, including seven companies including Jidan Bio, Yuexin Health, and China Resources Sanjiu, whose fields involved in vitro diagnosis, medical services, In traditional Chinese medicine, CRO and other industries, the performance of most companies is basically good news .
-
In the fourth quarter of 2021, the proportion of proprietary Chinese medicines in my country's hospital drug market ranks first
Time of Update: 2022-04-28
According to the China Hospital Drug Statistics Report released by Aikunwei, in the fourth quarter of 2021, the total sales of China's hospital drug market (sales of hospitals with more than 100 beds, calculated at the hospital purchase price) reached 223 billion yuan, a year-on-year increase of 2.
-
In order to accelerate innovation, domestic and foreign pharmaceutical companies have set off a wave of cooperation
Time of Update: 2022-04-28
On March 9, Voyager Therapeutics announced that it has entered into a licensing and research and development agreement with Novartis, which gives Novartis the right to acquire development rights to the innovative AAV capsids developed by Voyager's AAV capsid discovery platform, targeting three unpublished AAV capsids.
-
The wave of layoffs in the pharmaceutical industry has emerged again, Gilead, Bojian...
Time of Update: 2022-04-28
Dongpei Pharmaceuticals: Disbanding the sales team of Ouxiwei China On March 7, according to news released by various media, the Italian biopharmaceutical company Dongpei Pharmaceuticals has stopped promoting its Senaijiming eye drops (Ouxiwei) in China.
-
In 2022, immunotherapy will set off a wave of innovative cooperation!
Time of Update: 2022-04-28
On the whole, the industry believes that with the development of pharmaceutical companies and the continuous entry of capital, more and more immunotherapies and drugs are expected to be approved for marketing, bringing more good news to domestic patients with immune diseases and providing more New, affordable treatment options .
-
A batch of medicines and consumables in Qinghai Province will be greatly reduced in price!
Time of Update: 2022-04-28
On February 7, the Jiangsu Provincial Public Resource Trading Center issued a notice that the supply prices of 34 drugs produced by 28 pharmaceutical companies will be adjusted, including ceftriaxone sodium for injection from Chengdu Yuandong and methanesulfonic acid from Nanjing Chia Tai Tianqing.
-
The original research has wiped out the entire army of Guangdong's chronic disease drugs. The results are here!
Time of Update: 2022-04-28
The seven provinces include: Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang and the Corps Only 8 original research companies signed up, but the whole army was wiped out From the perspective of procurement rules, there is no distinction between the original research and reference preparations in terms of grouping.
-
The collection and reporting of TCM decoction pieces will be carried out in many places, and the industry will be reshaped soon!
Time of Update: 2022-04-28
For example, on March 10, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Center stated that in accordance with the requirements of the Sanming Procurement Alliance (Nationwide) Office's "Notice on Carrying out Data Reporting Work for Some Varieties of Chinese Herbal Pieces", it organized medical institutions in Shanxi Province to carry out centralized delivery of Chinese Herbal Pieces.
-
Chinese medicine formula granules are starting to hang on the net!
Time of Update: 2022-04-27
The traditional Chinese medicine formula granules used in the designated public medical institutions of medical insurance in our province shall be purchased and traded online through the Fujian Provincial Pharmaceutical Equipment Joint Price-Limited Sunshine Procurement Platform (hereinafter referred to as the provincial platform) .
-
10 varieties of 9 pharmaceutical companies have been reviewed!
Time of Update: 2022-04-27
On March 8, Fangsheng Pharmaceutical announced that the company received the "Approval Notice for Supplementary Drug Application" issued by the State Drug Administration for Cefixime Tablets, confirming that the drug has passed the quality and efficacy consistency evaluation of generic drugs.
-
Biogen acquires full control of Alzheimer's disease drug Aduhelm!
Time of Update: 2022-04-27
According to an announcement issued by both parties, the amendment to the agreement will take effect on January 1, 2023, and Eisai will receive tiered royalties based on Aduhelm's net sales, rather than sharing global profits and losses .
-
Hanyu Pharmaceutical's octreotide API obtained the EU CEP certificate
Time of Update: 2022-04-27
On March 16, 2022, Hanyu Pharmaceutical announced that its octreotide API has recently received the CEP (European Pharmacopoeia Applicability Certification) certificate issued by the European Medicines Agency .
Octreotide is a synthetic octapeptide derivative of natural somatostatin, its pharmacological action is similar to that of somatostatin, but the effect lasts longer .
-
Astellas' menopause drug fezolinetant fails clinical trial in Asia
Time of Update: 2022-04-27
Like the MOONLIGHT 1 Asian trial, two previously successfully completed Phase 3 studies, SKYLIGHT1 and SKYLIGHT2, also investigated changes in the frequency and severity of moderate-to-severe vasomotor symptoms (commonly referred to as hot flashes) in menopausal women .
-
The clinical trial application of ASK0912 for injection, a subsidiary of Osaikang, was accepted
Time of Update: 2022-04-27
On March 16, 2022, Osaikang issued an announcement stating that Jiangsu Osaikang Injection ASK0912, a wholly-owned subsidiary of the company, recently received the "Notice of Acceptance" for the application for new drug clinical trials issued by the NMPA .
-
In 2023, the scale of the traditional Chinese medicine formula granule industry will exceed 50 billion, and related companies have recently attracted attention
Time of Update: 2022-04-27
In the face of the considerable and accelerated standardized development of the traditional Chinese medicine formula granules market, related companies have attracted the attention of the industry .
-
Mirtazapine, a subsidiary of Minovar, passed the CDE technical review
Time of Update: 2022-04-27
On March 16, 2022, Minovar announced that its holding subsidiary Zhejiang Liaoyuan mirtazapine API has passed the CDE technical review, and the registration number will be displayed on the CDE API, ph
